Dyserythropoietic anemia, congenital type 3
| Congenital Dyserythropoietic Anemia Type III | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Anemia, jaundice, splenomegaly |
| Complications | Gallstones, iron overload |
| Onset | Birth or early childhood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | N/A |
| Diagnosis | Blood tests, bone marrow biopsy |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | Supportive care, blood transfusions |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | N/A |
| Deaths | N/A |
Congenital Dyserythropoietic Anemia Type III (CDA III) is a rare genetic disorder characterized by ineffective erythropoiesis and distinct morphological abnormalities in erythroblasts. It is one of the subtypes of congenital dyserythropoietic anemia (CDA), a group of hereditary anemias.
Etiology[edit]
CDA III is caused by mutations in the KIF23 gene, which is located on chromosome 15. This gene encodes a protein involved in the final stages of cell division, particularly in the separation of daughter cells. The mutation leads to abnormal cell division in erythroid precursors, resulting in the characteristic features of the disease.
Pathophysiology[edit]
The hallmark of CDA III is the presence of giant multinucleated erythroblasts in the bone marrow. These cells exhibit ineffective erythropoiesis, leading to anemia. The ineffective erythropoiesis is due to the inability of the erythroblasts to undergo normal mitosis and cytokinesis, resulting in the formation of these abnormal cells.
Clinical Features[edit]
Patients with CDA III typically present with:
- Anemia: This is usually mild to moderate and may be associated with fatigue and pallor.
- Jaundice: Due to increased breakdown of red blood cells.
- Splenomegaly: Enlargement of the spleen is common due to increased destruction of abnormal erythrocytes.
Complications can include:
- Gallstones: Due to increased bilirubin production.
- Iron overload: From repeated blood transfusions or increased intestinal iron absorption.
Diagnosis[edit]
Diagnosis of CDA III involves:
- Complete blood count (CBC) showing anemia.
- Peripheral blood smear revealing abnormal erythrocytes.
- Bone marrow biopsy demonstrating giant multinucleated erythroblasts.
- Genetic testing to identify mutations in the KIF23 gene.
Treatment[edit]
There is no cure for CDA III, and treatment is primarily supportive. Management strategies include:
- Regular blood transfusions to manage severe anemia.
- Iron chelation therapy to prevent iron overload.
- Splenectomy in cases of severe splenomegaly or hypersplenism.
Prognosis[edit]
The prognosis for individuals with CDA III is generally good, with most patients maintaining a reasonable quality of life with appropriate management. However, they require lifelong monitoring for complications such as iron overload.
